This Prolactin enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific for Prolactin. Standards or samples are then added to the microtiter plate wells and Prolactin if present, will bind to the antibody pre-coated on the wells. In order to quantitate the amount of Prolactin present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated monoclonal antibody, specific for Prolactin are added to each well to “sandwich” the Prolactin immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, a TMB (3,3',5,5' tetramethyl-benzidine) substrate solution is added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain Prolactin and enzyme-conjugated antibody will exhibit a change in colour. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the colour change is measured spectrophotometrically at a wavelength of 450 nm.

In order to measure the concentration of Prolactin in the sample, this Human Prolactin ELISA Kit includes a set of calibration standards (6 standards). The calibration standards are assayed at the same time as the samples and allow the operator to produce a standard curve of Optical Density (O.D.) versus Prolactin concentration (ng/mL). The concentration of Prolactin in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Plate-forme

Microplate

Méthode de détection

Colorimetric

Type d'échantillon

Serum

Sensibilité

< 1.5 ng/ml

Gamme de detection

1.5-200 ng/ml

Reactivité

Human

Réactivité croisée

This assay has shown no detectable cross-reactivity with human FSH, LH, and TSH, hCG and hGH.

Precision

Intra-assay CV: < 8%, Inter-assay CV: < 10%

Stockage

Store at 2-8°C.

Synonymes

AV290867, Decidual prolactin, GHA1, Growth hormone A1, Lactogenic Hormone , Luteotropic Hormone , Mammotropin, OTTMUSP00000000651, PRL, Prl1a1, Prol, Prolactin precursor , RATPRLSD1, RNPROL, RP23-351I6.2, RP3-404K8.1

Avertissement

Ce produit est uniquement destiné à la recherche. Il n'est pas destiné à un usage diagnostique ou thérapeutique.

Images (1)

Cliquez pour ouvrir le point de vue élargi

Figure 1: Standard Curve - Human Prolactin ELISA Kit (EL10014)

Representative Standard Curve using Human Prolactin ELISA Kit (EL10014).

Références (2)

Cliquez pour ouvrir le point de vue élargi

(3)

Isolation of tumour stem-like cells from benign tumours.

Références : Human Prolactin ELISA Kit (A32998)

Résumé :

BACKGROUND:

Cancerous stem-like cells (CSCs) have been implicated as cancer-initiating cells in a range of malignant tumours. Diverse genetic programs regulate CSC behaviours, and CSCs from glioblastoma patients are qualitatively distinct from each other. The intrinsic connection between the presence of CSCs and malignancy is unclear. We set out to test whether tumour stem-like cells can be identified from benign tumours.

METHODS:

Tumour sphere cultures were derived from hormone-positive and -negative pituitary adenomas. Characterisation of tumour stem-like cells in vitro was performed using self-renewal assays, stem cell-associated marker expression analysis, differentiation, and stimulated hormone production assays. The tumour-initiating capability of these tumour stem-like cells was tested in serial brain tumour transplantation experiments using SCID mice.

RESULTS:

In this study, we isolated sphere-forming, self-renewable, and multipotent stem-like cells from pituitary adenomas, which are benign tumours. We found that pituitary adenoma stem-like cells (PASCs), compared with their differentiated daughter cells, expressed increased levels of stem cell-associated gene products, antiapoptotic proteins, and pituitary progenitor cell markers. Similar to CSCs isolated from glioblastomas, PASCs are more resistant to chemotherapeutics than their differentiated daughter cells. Furthermore, differentiated PASCs responded to stimulation with hypothalamic hormones and produced corresponding pituitary hormones that are reflective of the phenotypes of the primary pituitary tumours. Finally, we demonstrated that PASCs are pituitary tumour-initiating cells in serial transplantation animal experiments.

CONCLUSION:

This study for the first time indicates that stem-like cells are present in benign tumours. The conclusions from this study may have applications to understanding pituitary tumour biology and therapies, as well as implications for the notion of tumour-initiating cells in general.

Afficher la publication

Raised prolactin levels in myasthenia gravis: two case reports and a study of two patient populations.

Références : Human Prolactin ELISA Kit (A32998)

Résumé :

OBJECTIVES:

To describe two patients with myasthenia gravis (MG) and prolactinoma and analyze the associations between MG and prolactin (PRL) levels.

DESIGN:

Two case reports and a case-control study of PRL levels in 192 patients with MG.

PARTICIPANTS:

The Immunological Research Laboratory, Center for Molecular Medicine, Department of Medicine and the Department of Neurology, Karolinska Institutet, Stockholm, Sweden; St Petersburg Medical Academy for Postgraduate Studies, and St Petersburg State Medical Pediatric Academy, Russia.

RESULTS:

Two women with MG and thymic hyperplasia accompanied by prolactinomas are described. The levels of plasma PRL were raised in 101 women with MG, but not in 91 men. There was an association between high PRL levels and high levels of autoantibodies against the acetylcholine receptor.

CONCLUSIONS:

There is an association of MG with raised levels of PRL in women. PRL has stimulating effects on immune activation and the increased levels might thus be implied in the pathophysiology of MG.

Afficher la publication